Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PYXS
$1.48
$
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
1.462
Average Volume
Market Cap
Last Dividend
CIK
0001782223
ISIN
US7473241013
CUSIP
747324101
CEO
Thomas Civik
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
44
IPO Date
2021-10-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages | Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the | Defense World | 2026-02-21 04:10:48 |
| Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity | BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. | GlobeNewsWire | 2026-02-03 06:45:00 |
| Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update | Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Currently, 4.1% of the company's stock are short sold. Based on an | Defense World | 2026-02-02 01:43:13 |
| Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages | Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. | Defense World | 2026-01-02 03:28:47 |
| Analysts Sound Alarm On Pyxis Oncology's Tiny Trial | Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). | Benzinga | 2025-12-19 09:07:43 |
| Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript | Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript | Seeking Alpha | 2025-12-18 14:57:37 |
| Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The update includes preliminary data from both the Phase 1 monotherapy study in 2L+ R/M HNSCC and the Phase 1/2 study evaluating MICVO in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, pembrolizumab, in 1L/2L+ R/M HNSCC. | GlobeNewsWire | 2025-12-18 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| EFFECT | 2025-12-09 | 2025-12-10 | View Filing |
| S-3 | 2025-11-26 | 2025-11-26 | View Filing |
| 10-Q | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| SC 13G/A | 2025-10-14 | 2025-10-14 | View Filing |
| SC 13G | 2025-09-23 | 2025-09-23 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| SC 13G/A | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-03 | 2025-07-02 | View Filing |
| SC 13G | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-06 | 2025-05-06 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| SC 13D/A | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| S-8 | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-02-04 | 2025-02-04 | View Filing |
| SC 13D/A | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 8-K | 2024-12-19 | 2024-12-19 | View Filing |
| SC 13G | 2024-12-16 | 2024-12-16 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 8-K | 2024-11-20 | 2024-11-20 | View Filing |
| S-8 | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-06 | 2024-11-06 | View Filing |
| 8-K | 2024-10-23 | 2024-10-23 | View Filing |
| DEF 14A | 2024-09-25 | 2024-09-25 | View Filing |
| PRE 14A | 2024-09-13 | 2024-09-13 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-06-12 | 2024-06-12 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 3 | 2024-06-10 | 2024-06-10 | View Filing |
| 8-K | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| EFFECT | 2024-04-04 | 2024-04-04 | View Filing |
| 424B2 | 2024-04-04 | 2024-04-03 | View Filing |
| SC 13D/A | 2024-04-03 | 2024-04-03 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| 4 | 2024-03-28 | 2024-03-28 | View Filing |
| S-3 | 2024-03-27 | 2024-03-27 | View Filing |
| 8-K | 2024-03-27 | 2024-03-27 | View Filing |
| 8-K | 2024-03-27 | 2024-03-27 | View Filing |
| S-8 | 2024-03-22 | 2024-03-21 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 4 | 2024-03-13 | 2024-03-13 | View Filing |
| 3 | 2024-03-13 | 2024-03-13 | View Filing |
| 8-K | 2024-03-13 | 2024-03-13 | View Filing |
| SC 13G | 2024-03-08 | 2024-03-08 | View Filing |
| 8-K | 2024-02-28 | 2024-02-28 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| RSI Overbought Strategy | 38.88% | 1.18 | 14 | 0.82 | 0.68 | 72.3 |
| Heikin Ashi Strategy | 36.34% | 0.91 | 7 | 0.66 | 0.75 | 69.76 |
| Williams PercentR Strategy | 30.26% | 0.98 | 26 | 0.6 | 0.31 | 63.68 |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | x |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |